|
SUO Board Meeting (Board Members Only)
Friday, May 28, 2010
Hilton San Francisco
5:00 p.m. – 10:00 p.m.
SUO/SBUR Joint Meeting (Morning Program)
Saturday, May 29, 2010
Hilton San Francisco, Grand Ballroom Salon B
7:55 a.m. – 11:25 a.m.
SUO Business Meeting (Members Only)
Saturday, May 29, 2010
Hilton San Francisco, Continental Ballroom 6
11:30 a.m. – 12:30 p.m.
SUO Annual Meeting (Afternoon Program)
Saturday, May 29, 2010
Hilton San Francisco, Grand Ballroom Salon B
12:30 p.m. – 5:00 p.m.
SUO Reception and Dinner
Saturday, May 29, 2010
Hilton San Francisco, Continental Ballroom 6
6:30 p.m. – 10:00 p.m.
SUO-CTC Board Meeting (Board Members Only)
Monday, May 31, 2010
Hilton San Francisco
10:00 a.m. – 12:00 p.m.
|
|
|
SUO/SBUR Educational Needs (Morning)
Topics featured at the 2010 combined meeting of the SUO and SBUR
will represent recent developments in the androgen receptor in prostate
cancer and imaging for genitourinary malignancies. Both of these
sessions will feature basic and translational research and emphasize
applications for the modern management of cancer patients.
SUO/SBUR Educational Objectives (Morning)
At the conclusion of the meeting, the attendee should be able to:
- Understand new developments regarding androgen signaling in
advanced prostate cancer
- Identify new approaches to modulating the androgen receptor for
therapeutic purposes in prostate cancer
- Comprehend hurdles associated with the development of new
imaging modalities
- Understand new approaches to the metabolic imaging of prostate
cancer
- Recognize the role the Ras pathway has in cancer and its
application to GU malignancies
SUO Needs (Afternoon)
Due to emerging data in genitourinary oncology, there is a need
to disseminate practical applications to the urologic oncology
community. The needs for this annual program were identified
through consensus of experts, interviews with the members of the
society, current literature, and assessments of other similar regional
and national urologic oncology meetings. These sources indicated
a need for further education in the recent reports of prostate cancer
screening and active surveillance, the current practice guidelines and
management strategies for small renal masses, the standard of care
for muscle-invasive bladder cancer, the acute and late toxicities of
testis cancer treatment and follow-up, and the state of prostate cancer
chemoprevention.
SUO Afternoon Objectives (Afternoon)
At the conclusion of the meeting, the attendee should be able to:
- Describe the pros and cons of prostate cancer screening.
- Identify the appropriate candidates for active surveillance and recite the disease-specific outcomes in active surveillance
populations.
- Discuss the evaluation of newly diagnosed small renal masses.
- Articulate the treatment options for small renal masses and identify
methods to reduce renal injury during treatment.
- Understand the current standard of care for treating muscleinvasive
bladder cancer and how to assess quality of care.
- Recognize the acute and late sequelae of testis cancer treatment
and follow-up, in particular the toxicities of chemotherapy,
radiotherapy, and imaging-associated radiation.
- Report the current state of chemoprevention for prostate cancer,
including optimal candidates for prevention strategies.
Accreditation: The American Urological Association (AUA) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
physicians.
The AUA takes responsibility for the content, quality, and scientific
integrity of this CME activity.
Credit Designation: The American Urological Association designates
this educational activity for a maximum of 7.50 AMA PRA Category 1
Credits™. Physicians should only claim credit commensurate with the
extent of their participation in the activity.
The combined SUO/SBUR morning session is designated for a
maximum of 3.00 AMA PRA Category 1 Credits™.
The SUO afternoon session is designated for a maximum of 4.50 AMA
PRA Category 1 Credits™.
AUA Disclosure Policy: As a provider accredited by the ACCME, the
AUA must ensure balance, independence, objectivity and scientific
rigor in all its activities.
All faculty participating in an educational activity provided by the
AUA are required to disclose to the provider any relevant financial
relationships with any commercial interest. The AUA must determine if
the faculty’s relationships may influence the educational content with
regard to exposition or conclusion and resolve any conflicts of interest
prior to the commencement of the educational activity.
Unlabeled or Unapproved Use of Drugs or Devices: It is the policy
of the AUA to require the disclosure of all references to unlabeled
or unapproved uses of drugs or devices prior to the presentation of
educational content. The audience is advised that this continuing
medical education activity may contain reference(s) to unlabeled or
unapproved uses of drugs or devices. Please consult the prescribing
information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty,
authors, and other experts whose input is included in this program are
their own and do not necessarily represent the viewpoint of the AUA.
Evidence Based Content: As a provider of continuing medical
education accredited by the ACCME, it is the policy of the AUA to review
and certify that the content contained in this CME activity is valid, fair,
balanced, scientifically rigorous, and free of commercial bias.
Special Assistance / Dietary Needs: The American Urological
Association (AUA), an organization accredited for Continuing Medical
Education (CME), complies with the Americans with Disabilities Act
§12112(a). If any participant is in need of special assistance or has any
dietary restrictions, a written request should be submitted at least one
month in advance. For additional assistance with your request please
call (847) 264-5901.
|
|
|
Society of Urologic Oncology Program
Saturday, May 29, 2010
Hilton San Francisco
San Francisco, California
The Morning Session is a combined meeting of:
The Society of Urologic Oncology & The Society of Basic Urologic Research
|
| |
|
|
MORNING SESSION
7:55 a.m. – 11:25 a.m.
Translation of Basic Science into Clinical Applications
Hilton San Francisco, Grand Ballroom Salon B
|
| |
|
| 7:55 a.m. – 8:00 a.m. |
Introduction and Welcome
David Jarrard, MD
University of Wisconsin
Eric Klein, MD
Cleveland Clinic
|
| |
|
|
RECENT DEVELOPMENTS IN ANDROGEN AXIS AND PROSTATE CANCER
Moderator: Robert Reiter, MD, University of California, Los Angeles
|
| 8:00 a.m. – 8:20 a.m. |
The Role of the Androgen Receptor in Castration-Resistant Prostate Cancer
Donald Tindall, PhD
Mayo Clinic College of Medicine
|
| 8:20 a.m. – 8:40 a.m. |
Intracrine Metabolism of Testicular Androgens by Castration-Recurrent Prostate Cancer – Are There Opportunities for Novel Treatments?
James Mohler, MD
Roswell Park Cancer Center
|
| 8:40 a.m. – 9:00 a.m. |
Small Molecule Inhibitors of the Amino-Terminal Domain of the Androgen Receptor
Marianne Sadar, PhD
BC Cancer Agency
|
| 9:00 a.m. – 9:15 a.m. |
Podium Discussion
|
| |
|
|
IMAGING GENITOURINARY MALIGNANCIES
Moderator: Tracy Downs, MD, University of Wisconsin
|
| 9:15 a.m. – 9:35 a.m. |
Hot Issues in Development of Imaging Agents: Focus on PSMA
Warren Heston, PhD
Cleveland Clinic Foundation
|
| 9:35 a.m. – 9:55 a.m. |
Novel Prostate Cancer Metabolic Imaging Approaches
John Kurhanewicz, PhD
University of California, San Francisco
|
| 9:55 a.m. – 10:15 a.m. |
Urologic Applications of Lymphoseek, a New Radiopharmaceutical for Sentinel Lymph Node Mapping
David Vera, MD
University of California, San Diego
|
| 10:15 a.m. – 10:30 a.m. |
Podium Discussion
|
| |
|
|
The Coffey Lectureship
|
| 10:30 a.m. – 11:25 a.m. |
Targeting the Ras Pathway
Frank McCormick, MD
UCSF Helen Diller Family Comprehensive Cancer Center
|
| 11:30 a.m. – 12:30 p.m. |
SUO Business Meeting
Location: Continental Ballroom 6
|
| |
|
|
AFTERNOON SESSION
12:30 p.m. – 5:00 p.m.
Hilton San Francisco, Grand Ballroom Salon B
|
| |
|
| 12:30 p.m. – 12:45 p.m. |
Welcome and Introductions
Eric Klein, MD
Cleveland Clinic
Presentation of CapCure Awards
Stuart Holden, MD
Prostate Cancer Foundation
Program Overview
Daniel Lin, MD
University of Washington
|
| 12:45 p.m. – 1:15 p.m. |
Whitmore Lecture
Joel Sheinfeld, MD
Memorial Sloan-Kettering Cancer Center
|
| 1:20 p.m. – 1:50 p.m. |
Prostate Cancer I – Screening: Lessons from the PLCO and ESRPC Randomized Trials
Moderator: Judd Moul, MD
Duke University Medical Center
|
|
1:20 p.m. – 1:30 p.m.
|
Pro: Peter Scardino, MD
Memorial Sloan-Kettering Cancer Center
|
|
1:30 p.m. – 1:40 p.m.
|
Con: TBD |
|
1:40 p.m. – 1:50 p.m.
|
Panel Discussion |
| |
|
| 1:55 p.m. – 2:25 p.m. |
Prostate Cancer II – Active Surveillance
Moderator: Ian Thompson, MD
University of Texas Health Science Center
|
|
1:55 p.m. – 2:05 p.m.
|
Pro: H. Ballantine Carter, MD
Johns Hopkins Hospital School of Medicine |
|
2:05 p.m. – 2:15 p.m.
|
Con: William Catalona, MD
Northwestern University Feinberg School of Medicine
|
|
2:15 p.m. – 2:25 p.m.
|
Panel Discussion
|
| |
|
| 2:30 p.m. – 3:10 p.m. |
Renal Cell Carcinoma – Evaluation and Management of the Small Renal Mass
Moderator: Chris Wood, MD
MD Anderson Cancer Center
|
|
2:30 p.m. – 2:40 p.m.
|
Optimizing the Treatment of Small Renal masses and AUA Guidelines.
Steven Campbell, MD
Cleveland Clinic Foundation
|
|
2:40 p.m. – 2:47 p.m.
|
Minimally Invasive Treatments of Small Renal Masses Lap/Robotic partial
Surena Matin, MD
MD Anderson Cancer Center
|
|
2:47 p.m. – 2:54 p.m.
|
Thermal Ablation
Thomas Jarrett, MD
George Washington University Medical Center
|
|
2:54 p.m. – 3:01 p.m.
|
Observation of Small Renal Masses
Robert Uzzo, MD
Fox Chase Cancer Center
|
|
3:01 p.m. – 3:10 p.m.
|
Methods to Reduce Acute Kidney Injury
Matthew Simmons, MD, PhD
Cleveland Clinic
|
|
|
|
| 3:15 p.m. – 4:00 p.m. |
Invasive Bladder Cancer: What is the Contemporary Standard of Care?
Moderator: Michael Cookson, MD
Vanderbilt University
|
|
3:15 p.m. – 3:20 p.m.
|
Introduction
Moderator: Michael Cookson, MD
Vanderbilt University
|
|
3:20 p.m. – 3:30 p.m.
|
Open Radical Cystectomy
Eila Skinner, MD
Keck USC School of Medicine
|
|
3:30 p.m. – 3:40 p.m.
|
Robotic-Assisted Radical Cystectomy
Raj Pruthi, MD
University of North Carolina, Chapel Hill
|
|
3:40 p.m. – 3:50 p.m.
|
Assessing Quality Control and in Surgery
Bernard Bochner, MD
Memorial Sloan-Kettering Cancer Center
|
|
3:50 p.m. – 4:00 p.m.
|
Panel Discussion and Case Presentations |
| |
|
| 4:00 p.m. – 4:30 p.m. |
Testis Cancer – Acute and Late Sequelae of Testis Cancer Treatment and Follow-Up
Moderator: Paul Lange, MD
University of Washington
|
|
4:00 p.m. – 4:10 p.m.
|
Chemotherapy-Related Toxicity
George Bosl, MD
Memorial Sloan-Kettering Cancer Center
|
|
4:10 p.m. – 4:20 p.m.
|
Radiation-Induced Toxicity
Sophie Fossa, MD
Radiumhospitalet Medical Centre
|
|
4:20 p.m. – 4:30 p.m.
|
Risk of Secondary Malignancy Associated with Serial Imaging for Cancer Follow-Up
Michael Jewett, MD
Princess Margaret Hospital
|
| |
|
| 4:35 p.m. – 5:15 p.m. |
Prostate Cancer III – Chemoprevention: Ready for Primetime?
With the Evidence Available, What is the State of Chemoprevention for Prostate Cancer?
Moderator: Neil Fleshner, MD
University Health Network
|
|
4:35 p.m. – 4:40 p.m.
|
Introduction
Moderator: Neil Fleshner, MD
University Health Network
|
|
4:40 p.m. – 4:50 p.m.
|
5-alpha Reductase Inhibitors Increase PSA Performance
Gerald Andriole, MD
Washington University Medical School
|
|
4:50 p.m. – 5:00 p.m.
|
5-alpha Reductase Inhibitors Impair Prostate Cancer Screening
Patrick Walsh, MD
Johns Hopkins Hospital School of Medicine
|
|
5:00 p.m. – 5:15 p.m.
|
Panel and Case Discussion
Who is Best Candidate for 5ARI?
|
| |
|
|
5:15 p.m. |
Adjourn
|
| |
|